Jefferies Financial Group Forecasts Strong Price Appreciation for Insmed (NASDAQ:INSM) Stock

Insmed (NASDAQ:INSM) had its price objective lifted by analysts at Jefferies Financial Group from $129.00 to $148.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price would suggest a potential upside of 15.85% from the company’s current price.

A number of other research firms also recently weighed in on INSM. Mizuho raised their price target on shares of Insmed from $130.00 to $165.00 and gave the company an “outperform” rating in a report on Wednesday. Citigroup upgraded Insmed to a “buy” rating in a report on Tuesday, June 10th. Leerink Partners boosted their price target on Insmed from $100.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 10th. JPMorgan Chase & Co. increased their price objective on Insmed from $90.00 to $111.00 and gave the company an “overweight” rating in a report on Tuesday, July 8th. Finally, The Goldman Sachs Group boosted their target price on Insmed from $100.00 to $112.00 and gave the stock a “buy” rating in a report on Wednesday, June 11th. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $129.57.

Insmed Stock Up 4.0%

Shares of Insmed stock opened at $127.75 on Wednesday. The firm has a market cap of $27.00 billion, a price-to-earnings ratio of -22.37 and a beta of 0.95. The stock has a 50-day simple moving average of $102.53 and a 200-day simple moving average of $83.54. Insmed has a 52-week low of $60.40 and a 52-week high of $128.48. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). The business had revenue of $107.42 million for the quarter, compared to the consensus estimate of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. Insmed’s revenue was up 18.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.94) EPS. On average, equities research analysts expect that Insmed will post -4.56 earnings per share for the current fiscal year.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 129,805 shares of the firm’s stock in a transaction on Monday, June 16th. The shares were sold at an average price of $100.39, for a total value of $13,031,123.95. Following the sale, the chief executive officer owned 233,924 shares in the company, valued at approximately $23,483,630.36. This trade represents a 35.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Sara Bonstein sold 58,400 shares of the business’s stock in a transaction on Monday, July 21st. The stock was sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the transaction, the chief financial officer directly owned 73,505 shares in the company, valued at $7,546,758.35. This trade represents a 44.27% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 525,716 shares of company stock worth $49,665,671 over the last three months. 3.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Insmed

Hedge funds have recently made changes to their positions in the stock. Cullen Frost Bankers Inc. increased its stake in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 221 shares during the period. Elequin Capital LP acquired a new stake in shares of Insmed during the 4th quarter worth approximately $28,000. ORG Partners LLC increased its position in shares of Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 196 shares during the period. Hilltop National Bank bought a new stake in shares of Insmed during the second quarter valued at approximately $28,000. Finally, FNY Investment Advisers LLC acquired a new position in shares of Insmed in the second quarter valued at $33,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.